HistoIndex Launches AI-Based FibroSIGHT Plus for Enhanced Fibrosis Assessment

HistoIndex has launched FibroSIGHT Plus, its second Laboratory Developed Test (LDT) in the United States, announced in a press release. This new test builds on the earlier FibroSIGHT by incorporating automated quantitative analysis of fibrosis, a significant advancement for diagnosing and tracking Metabolic Dysfunction-associated Steatohepatitis (MASH).

At the core of FibroSIGHT Plus is qFibrosis, HistoIndex's proprietary AI-driven algorithm. This technology leverages stain-free Second Harmonic Generation (SHG) imaging to automatically quantify multiple fibrosis-related collagen features in liver biopsies. The result is a continuous scale measurement of fibrosis, offering detailed insights into disease severity and enabling clinicians to better characterize and monitor patients over time.

FibroSIGHT Plus provides a standardized and objective measurement across biopsy specimens, reducing variability and enhancing confidence in fibrosis assessment. This advancement supports more personalized and data-driven treatment decisions, marking a significant step forward in integrating digital pathology solutions into routine patient care.